Novonesis

400.3

DKK

-0.07 %

Less than 1K followers

NSIS B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

-0.07%

-1.18%

-1.82%

-1.89%

-15.96%

-1.38%

-8.31%

+38.27%

+981.89%

Novonesis is a biochemistry company. The company develops enzymes and various microorganisms for industrial use. The enzymes are a protein used in a number of different industries, mainly in the agricultural and food industries. Novonesis products are used in various foods and clothing and the company holds sales on a global level. Novonesis was founded in 1921 and is headquartered in Bagsværd, Denmark.

Market cap

187.46B DKK

Turnover

15.74M DKK

Revenue

28.59B

EBIT %

13.07 %

P/E

80.11

Dividend yield-%

1.04 %

Financial calendar

3/4

2025

General meeting '25

4/4

2025

Half year dividend

13/8

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press releaseyesterday

Transactions under Novonesis’ share buyback program

Regulatory press release3/17/2025, 10:36 AM

Transactions under Novonesis’ share buyback program

Regulatory press release3/11/2025, 11:00 AM

Invitation to the Annual General Meeting

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/10/2025, 2:08 PM

Transactions under Novonesis’ share buyback program

Regulatory press release3/6/2025, 1:22 PM

Trading by management and close relations of management

Regulatory press release3/5/2025, 12:51 PM

Election of employee representatives to the Board of Directors

Regulatory press release3/5/2025, 8:33 AM

Trading by management and close relations of management

Regulatory press release3/5/2025, 7:41 AM

Initiation of share buyback program

Regulatory press release3/3/2025, 11:15 AM

Trading by management and close relations of management

Regulatory press release2/27/2025, 8:39 AM

Trading by management and close relations of management

Press release2/26/2025, 7:04 AM

12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025

Regulatory press release2/26/2025, 6:58 AM

12M 2024 Company announcement

Press release2/21/2025, 11:24 AM

Change to the Executive Leadership Team

Press release2/11/2025, 6:12 AM

Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance

Regulatory press release2/11/2025, 5:56 AM

Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance

Regulatory press release1/3/2025, 10:23 AM

Trading by management and close relations of management

Regulatory press release12/17/2024, 9:00 AM

Change to Novonesis’ Board of Directors

Regulatory press release11/29/2024, 2:22 PM

Major shareholder announcement

Regulatory press release11/27/2024, 10:09 AM

Major shareholder announcement

Regulatory press release11/25/2024, 12:43 PM

Major shareholder announcement

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.